Ascendis Pharma A/S (ASND) Raised to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a hold rating to a buy rating in a research note released on Tuesday. Zacks Investment Research currently has $22.00 price objective on the stock.

According to Zacks, “Ascendis Pharma A/S is a biopharmaceutical company. The company’s product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. “

Several other equities analysts also recently commented on the company. Wedbush started coverage on Ascendis Pharma A/S in a research report on Monday, September 26th. They issued an outperform rating and a $34.00 price objective on the stock. TheStreet upgraded Ascendis Pharma A/S from a sell rating to a hold rating in a research report on Tuesday, September 6th. Finally, Leerink Swann restated a buy rating on shares of Ascendis Pharma A/S in a research report on Friday, September 2nd.

Ascendis Pharma A/S (NASDAQ:ASND) traded up 0.30% during trading on Tuesday, reaching $20.08. The company had a trading volume of 1,170 shares. The firm’s 50 day moving average is $19.46 and its 200 day moving average is $16.20. Ascendis Pharma A/S has a one year low of $11.92 and a one year high of $21.70. The company’s market capitalization is $505.88 million.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, August 31st. The company reported ($0.59) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.10. Ascendis Pharma A/S had a negative return on equity of 47.61% and a negative net margin of 818.32%. On average, equities research analysts predict that Ascendis Pharma A/S will post ($3.14) earnings per share for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

5 Day Chart for NASDAQ:ASND

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.